Posted On: 11/03/2015 12:58:22 PM
Post# of 43
The Company is focused on the design and development of medical devices that use neuroblocking technology to treat obesity, metabolic
diseases and other gastrointestinal disorders and currently has approvals to commercially launch the Maestro Rechargeable System in the United
States and in Australia, the European Economic Area and other countries that recognize the European CE Mark. The Company has devoted
substantially all of its resources to recruiting personnel, developing its product technology, obtaining patents to protect its intellectual property
and raising capital, and has recently commenced commercial operations in the United States deriving revenues from its primary business activity
in 2015
diseases and other gastrointestinal disorders and currently has approvals to commercially launch the Maestro Rechargeable System in the United
States and in Australia, the European Economic Area and other countries that recognize the European CE Mark. The Company has devoted
substantially all of its resources to recruiting personnel, developing its product technology, obtaining patents to protect its intellectual property
and raising capital, and has recently commenced commercial operations in the United States deriving revenues from its primary business activity
in 2015
(0)
(0)
Here We Go!!!!
